A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and efficacy of elezanumab in
 participants with relapsing Multiple Sclerosis (RMS).
Inclusion Criteria:

 -  Participant has diagnosis of relapsing remitting multiple sclerosis (RRMS) or
 secondary-progressive multiple sclerosis (SPMS) with relapses within the past 24
 months.

 -  Participant has cranial magnetic resonance imaging (MRI) demonstrating lesion(s)
 consistent with multiple sclerosis (MS).

 -  Participant has evidence of physical disability according to Expanded Disability
 Status Scale (EDSS) or Timed 25-Foot Walk (T25FW) or 9-Hole Peg Test.

 Exclusion Criteria:

 -  Participants must not have experienced or be recovering from a clinical MS relapse
 within 6 months of Screening.